Abbott Laboratories $ABT Shares Sold by Key Client Fiduciary Advisors LLC

Key Client Fiduciary Advisors LLC lessened its holdings in shares of Abbott Laboratories (NYSE:ABT) by 77.5% during the 4th quarter, Holdings Channel.com reports. The fund owned 1,829 shares of the healthcare product maker’s stock after selling 6,286 shares during the period. Key Client Fiduciary Advisors LLC’s holdings in Abbott Laboratories were worth $229,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in ABT. Harbor Capital Advisors Inc. acquired a new stake in shares of Abbott Laboratories during the 4th quarter worth about $27,000. Cloud Capital Management LLC acquired a new position in Abbott Laboratories during the third quarter worth approximately $29,000. Guerra Advisors Inc acquired a new position in Abbott Laboratories during the third quarter worth approximately $31,000. Bridge Generations Wealth Management LLC acquired a new position in Abbott Laboratories during the third quarter worth approximately $33,000. Finally, Copia Wealth Management acquired a new position in Abbott Laboratories during the third quarter worth approximately $38,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Trading Down 1.0%

NYSE:ABT opened at $91.78 on Thursday. The firm has a market cap of $159.85 billion, a P/E ratio of 25.71, a PEG ratio of 1.55 and a beta of 0.79. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19. The stock’s 50 day simple moving average is $106.77 and its 200-day simple moving average is $117.81. Abbott Laboratories has a 12-month low of $91.59 and a 12-month high of $139.06.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. The business had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a return on equity of 17.71% and a net margin of 13.90%.The company’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities analysts anticipate that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.7%. Abbott Laboratories’s payout ratio is presently 70.59%.

Insiders Place Their Bets

In other news, VP John A. Jr. Mccoy sold 585 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $67,614.30. Following the transaction, the vice president owned 24,628 shares of the company’s stock, valued at approximately $2,846,504.24. The trade was a 2.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Mary K. Moreland sold 613 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $70,850.54. Following the completion of the transaction, the executive vice president directly owned 104,291 shares in the company, valued at approximately $12,053,953.78. The trade was a 0.58% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 3,055 shares of company stock valued at $353,097. 0.46% of the stock is owned by company insiders.

Analyst Ratings Changes

ABT has been the topic of several research analyst reports. JPMorgan Chase & Co. cut their price target on Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating on the stock in a research report on Friday, April 17th. Freedom Capital raised Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 29th. Piper Sandler cut their price target on Abbott Laboratories from $135.00 to $115.00 and set an “overweight” rating on the stock in a research report on Friday, April 17th. Raymond James Financial cut their price target on Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Finally, Leerink Partners cut their price target on Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a research report on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $119.43.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Dividend/income stories are drawing buyer interest — multiple outlets highlight a near-3% dividend yield and buy-the-dip arguments for this dividend king, which can attract income-focused investors and support the share price. Abbott Laboratories Just Got Interesting: Dividend Yield Near 3% Signals Opportunity
• Positive Sentiment: Additional buy-the-dip commentary from retail/investor media emphasizes long-term fundamentals and steady dividend cashflow as reasons to accumulate, providing some demand at lower prices. Abbott Laboratories: Buy The Dip On This Dividend King
• Positive Sentiment: UBS reiterated a Buy rating on ABT (despite lowering its price target), which signals continued institutional conviction in Abbott’s longer-term prospects and may cap downside from short-term selling. UBS Sticks to Their Buy Rating for Abbott Laboratories (ABT)
• Positive Sentiment: Sector tailwinds: a large industry report forecasts rapid long-term growth for IoT/connected medical devices — a positive backdrop for Abbott’s device and diagnostics businesses over the next decade. IoT Medical Devices Market Research and Global Forecast Report 2026-2036
• Neutral Sentiment: Options market activity has picked up, prompting speculation of an imminent move; this can amplify intraday volatility but is ambiguous on direction. Is the Options Market Predicting a Spike in Abbott Laboratories Stock?
• Neutral Sentiment: Coverage noting ABT as “most oversold” in the healthcare group highlights technical conditions that could prompt short-term rebounds or continued mean reversion — not a definitive catalyst. Abbott is the most oversold healthcare stock as Q1 earnings roll on
• Neutral Sentiment: Heightened investor attention (search/traffic spikes) signals retail/institutional focus but does not predetermine direction; could increase volume and volatility. Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
• Negative Sentiment: Analyst downgrade: Daiwa cut ABT from Outperform to Neutral and set a $92 PT — this increases near-term selling pressure, especially given the PT is close to current levels. Finviz (Daiwa downgrade)
• Negative Sentiment: Several firms trimmed price targets (Argus, Leerink; UBS also cut its target while keeping Buy) and Barclays lowered expectations — collectively these lower benchmarks reduce upside perception and likely contributed to today’s downward pressure. UBS adjusts Abbott price target
• Negative Sentiment: Media stories pointing out ABT trading near 52-week lows — even with analyst optimism — can prompt profit-taking by momentum traders and feed negative sentiment. Wall Street Refuses to Blink: 2 Healthcare Stocks at 52-Week Lows That Analysts Still Love

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.